- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nucletron expands exec ranks
Three new vice presidents have joined the executive ranks of brachytherapy provider Nucletron.
Nucletron expands exec ranks
Three new vice presidents have joined the executive ranks of brachytherapy provider Nucletron. As vice president of global marketing, Jan Boers will be responsible for worldwide marketing and communications, joining the firm after serving in roles at CSM Food, Heinz, and Sara Lee International. John Lapré takes over as Nucletron's vice president of research and development following his most recent stint as VP of research and development for CP Kelco. Bringing nearly 20 years of international experience in the pharmaceutical industry, Dr. Jonathan Briers leads the company’s newly created medical affairs department, having served in product management and medical affairs at Servier International, SmithKline Beecham and, most recently, at Pfizer. Briers previously held appointments at the University of Manchester Medical School in the U.K. and clinical posts in Manchester and Liverpool.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
